Compare NEXA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXA | CGEM |
|---|---|---|
| Founded | 1956 | 2016 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.7M | 671.7M |
| IPO Year | 2017 | 2021 |
| Metric | NEXA | CGEM |
|---|---|---|
| Price | $7.67 | $10.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $6.20 | ★ $28.00 |
| AVG Volume (30 Days) | 342.5K | ★ 1.4M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,839,970,000.00 | N/A |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $1.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.95 | N/A |
| 52 Week Low | $4.44 | $5.68 |
| 52 Week High | $9.61 | $13.33 |
| Indicator | NEXA | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 64.81 | 47.91 |
| Support Level | $7.11 | $10.01 |
| Resistance Level | $8.44 | $13.10 |
| Average True Range (ATR) | 0.38 | 0.99 |
| MACD | 0.03 | -0.16 |
| Stochastic Oscillator | 61.03 | 2.59 |
Nexa Resources SA is a low-cost integrated zinc producer. It produces copper, silver, and gold as byproducts. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.